FT 8225
Alternative Names: FT-8225Latest Information Update: 28 Sep 2023
At a glance
- Originator FORMA Therapeutics
- Class Hepatoprotectants
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 01 Aug 2019 Forma Therapeutics has patent protection for FT 8225 and its use for treating nonalcoholic steatohepatitis in World before August 2019 (Forma Therapeutics pipeline, August 2019)